Clinical Trial Update: Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma [Phase 2]

View source ↗

Summary

Valemetostat tosylate is being studied as a single-agent therapy for relapse or refractory B-cell lymphoma in a Phase 2 trial, which is currently active but not…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• Valemetostat Tosylate (valemetostat tosylate)

Snippet

Sponsor: The Lymphoma Academic Research Organisation | Conditions: Lymphoma, B-Cell | Phase 2 | Status: ACTIVE_NOT_RECRUITING